BCAX

insider transactions

Bicara Therapeutics Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 90d

-78.9K

0 buy · 78.9K sell

Net value · 90d

-$1.7M

$0 in · $1.7M out

Sentiment · 90d

Net selling

0% buying · 100% selling

Open-market trades · 90d

0 buy · 78.9K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

Transactions · 90d

Open-market Buys Sells All types

Sell·S
May 21, 26

Hyep Ivan KEY

Chief Financial Officer · 10b5-1

$187.9K

9.2K sh · $20.42

Own -6%
Sell·S
May 18, 26

Mazumdar Claire KEY

Chief Executive Officer · 10b5-1

$300.6K

15.0K sh · $20.04 avg · 2 lots

Own -4%
Sell·S
May 15, 26

Cohlhepp Ryan KEY

President and COO · 10b5-1

$253.6K

12.5K sh · $20.29 avg · 2 lots

Own -6%
Sell·S
Apr 27, 26

Raben David

Chief Medical Officer · 10b5-1

$125.8K

5.5K sh · $22.88

Own -9%
Sell·S
Apr 21, 26

Hyep Ivan KEY

Chief Financial Officer · 10b5-1

$211.6K

9.2K sh · $23.00

Own -6%
Sell·S
Apr 20, 26

Mazumdar Claire KEY

Chief Executive Officer · 10b5-1

$354.1K

15.0K sh · $23.61

Own -4%
Sell·S
Apr 15, 26

Cohlhepp Ryan KEY

President and COO · 10b5-1

$287.6K

12.5K sh · $23.01 avg · 2 lots

Own -6%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
May 21, 2026	Hyep Ivan KEY 10b5-1	Chief Financial Officer	Sell S	9.2K	-6%	$20.42	$187.9K
May 18, 2026	Mazumdar Claire KEY 10b5-1	Chief Executive Officer	Sell S	15.0K2 lots	-4%	$20.04 avg	$300.6K
May 15, 2026	Cohlhepp Ryan KEY 10b5-1	President and COO	Sell S	12.5K2 lots	-6%	$20.29 avg	$253.6K
Apr 27, 2026	Raben David 10b5-1	Chief Medical Officer	Sell S	5.5K	-9%	$22.88	$125.8K
Apr 21, 2026	Hyep Ivan KEY 10b5-1	Chief Financial Officer	Sell S	9.2K	-6%	$23.00	$211.6K
Apr 20, 2026	Mazumdar Claire KEY 10b5-1	Chief Executive Officer	Sell S	15.0K	-4%	$23.61	$354.1K
Apr 15, 2026	Cohlhepp Ryan KEY 10b5-1	President and COO	Sell S	12.5K2 lots	-6%	$23.01 avg	$287.6K

Buy Sell Non-market (grant · exercise · gift)

About BCAX insider trading

This page tracks insider transactions for Bicara Therapeutics Inc. (BCAX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.